FIGURE 6.

Western blot analysis of the expression of EGF receptor (EGFR), phosphorylated (p-)EGFR, p-ERK1/2, and p-ERK5. A: In the whole liver EGFR and p-EGFR expression were similarly detected in control and PCK rats without gefitinib treatment. Treatment with gefitinib (10 mg/kg) diminished p-EGFR expression in the liver. Expression of p-ERK5 was increased in the untreated PCK liver, which reduced after gefitinib treatment. B: In the kidney, expression levels of EGFR were weaker compared with those in the liver, and the expression of p-EGFR was faint or invisible, even in the untreated kidney. Increased expression of p-ERK1/2 was observed in untreated PCK kidney, and the expression was unchanged after gefitinib treatment. C: In cultured BECs, p-ERK5 was overexpressed in PCK rats, and the expression was reduced after gefitinib treatment. Data represent four independent experiments.